FTC Blocks Edwards Lifesciences’ $945M JenaValve Acquisition - Orange County Business Journal

Edwards Acquisition of JenaValve Called Off

January 12, 2026—Edwards Lifesciences announced that it will not be acquiring JenaValve Technology, a developer of transcatheter treatments for aortic regurgitation (AR). According to Edwards, the decision follows the US District Court for the District of Columbia’s grant of a motion by the Federal Trade Commission (FTC) for an injunction blocking the proposed acquisition of JenaValve, which was first announced in July 2024. In August 2025, the …

FTC Blocks Edwards Lifesciences’ $945M JenaValve Acquisition - Orange County Business Journal

Edwards Lifesciences Corp. is no longer acquiring structural heart company JenaValve Technology for $945 million after a U.S. District Court granted the Federal Trade Commission’s motion for an injunction blocking the deal. Edwards said that it disagrees with the decision and “believes that the acquisition would have been in the best interest of a large, growing and underserved group of patients.” As a result, the company is revising its full ye…